Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Could Electromagnetic Treatment Reverse Memory Loss in Alzheimer’s Disease Patients?

XTALKS VITALS NEWS

Alzheimer's Disease

Preclinical data on the NeuroEM 1000 medical device showed that the technology was able to prevent – and even reverse – memory loss in mice models of Alzheimer’s disease.

Share this!

December 7, 2016 | by Sarah Hand, M.Sc.

A medical device which provides transcranial electromagnetic treatment (TEMT) to the brain, is being investigated in a new clinical trial involving patients with Alzheimer’s disease. The device – known as the NeuroEM 1000 – was developed by medical device company, NeuroEM Therapeutics.

The Phase I clinical trial will be conducted over a 2-month period by researchers at Banner Sun Health Research Institute and Banner Alzheimer's Institute, both in Phoenix, Arizona. Preclinical data on the NeuroEM 1000 medical device showed that the technology was able to prevent – and even reverse – memory loss in mice models of Alzheimer’s disease.

“We are very pleased to have two of the country's most notable and trusted Alzheimer's research institutes performing this first-of-its-kind clinical trial,” said Dr. Gary Arendash, President and CEO of NeuroEM Therapeutics. “Although the Phase I trial is primarily to investigate safety of the TEMT head device, a number of measures have been included in the trial's design that could provide evidence of therapeutic efficacy.”



According to NeuroEM Therapeutics, the TEMT is thought to disrupt the amyloid protein aggregates in the brain which are associated with Alzheimer’s pathology. The technology also stimulates mitochondrial functioning to increase energy production in brain cells damaged by Alzheimer’s.

Patients enrolled in the clinical trial of the NeuroEM 1000 device will receive TEMT treatments administered by their caregiver. As the medical device only needs to be worn twice per day for one-hour treatments, Alzheimer’s patients participating in the study do not need to travel to a clinical trial site in order to complete their therapy.

Drug development in the Alzheimer’s space has been slow and fraught with clinical failures. NeuroEM Therapeutics believes that neuromodulatory disease interventions could be more successful in treating the neurodegenerative disorder.

The TEMT technology was developed by Arendash and his colleagues at the Florida Alzheimer's Disease Research Center. The study coordinators expect that the results of the Phase I Alzheimer’s clinical trial will be released in Spring 2018.


Keywords: Alzheimer's Disease, Medical Device, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.